Is Tarlatamab-Imdelltra covered by health insurance?

Tarlatamab-Imdelltra is a new tumor immunotherapy drug that has attracted much attention in recent years. It was approved by the US FDA in May 2024. This is a first-of-its-kind bispecific T cell engager (BiTE) drug that can simultaneously bind to the DLL3 protein on the surface of small cell lung cancer cells and the patient's own CD3 T cells to achieve precise immune attack. DLL3 is considered to be a molecule that is highly expressed specifically in extensive-stage small cell lung cancer (ES-SCLC) but is hardly expressed in normal tissues, making it an important target. Through this mechanism, talatumumab effectively "draws" T cells to the surface of tumor cells and initiates the killing effect, forming a new treatment model.

In terms of indications, talatumumab is currently approved for the treatment of adult patients with extensive-stage small cell lung cancer whose disease has progressed during or after platinum-based chemotherapy. Small cell lung cancer is an extremely malignant and rapidly progressing lung tumor, accounting for 10% to 15% of lung cancer cases. Although sensitive to chemoradiotherapy, patients often suffer from early relapse and drug resistance, and traditional treatments are limited. Therefore, the approval of talatumumab provides new hope for these patients.

However, as far as the domestic situation is concerned, talatumumab is not yet on the market in China, let alone included in the medical insurance catalog. This means that patients are temporarily unable to use the drug through medical insurance reimbursement channels and can only rely on overseas drug purchases. However, judging from the country’s emphasis on the introduction of innovative drugs and drugs for rare tumor indications in recent years, talatumumab may accelerate its entry into the Chinese market in the future.

Overall, talatumumab has precise indications and innovative immune mechanisms, providing a new treatment option for extensive-stage small cell lung cancer. However, as there is currently no news on domestic launch and medical insurance reimbursement, patients still have to wait for its further progress in the Chinese market.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html